Correction: Differentiating HER2-low and HER2-zero tumors with 21-gene multigene assay in 2,295 HR + HER2- breast cancer: a retrospective analysis
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Correction: Differentiating HER2-low and HER2-zero tumors with 21-gene multigene assay in 2,295 HR + HER2- breast cancer: a retrospective analysis ; volume:26 ; number:1 ; day:26 ; month:11 ; year:2024 ; pages:1 ; date:12.2024
Breast cancer research ; 26, Heft 1 (26.11.2024), 1, 12.2024
- Urheber
-
Kook, Yoonwon
Lee, Young-jin
Chu, Chihhao
Jang, Ji Soo
Baek, Seung Ho
Bae, Soong June
Cha, Yoon Jin
Gong, Gyungyup
Jeong, Joon
Lee, Sae Byul
Ahn, Sung Gwe
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s13058-024-01929-z
- URN
-
urn:nbn:de:101:1-2502112156299.793705062713
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:21 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Kook, Yoonwon
- Lee, Young-jin
- Chu, Chihhao
- Jang, Ji Soo
- Baek, Seung Ho
- Bae, Soong June
- Cha, Yoon Jin
- Gong, Gyungyup
- Jeong, Joon
- Lee, Sae Byul
- Ahn, Sung Gwe
- SpringerLink (Online service)
Ähnliche Objekte (12)
Differentiating HER2-low and HER2-zero tumors with 21-gene multigene assay in 2,295 HR + HER2- breast cancer: a retrospective analysis
Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
Survival outcomes in HER2-low versus HER2-zero breast cancer after neoadjuvant chemotherapy: a meta-analysis
HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates
Dual targeting non-overlapping epitopes in HER2 domain IV substantially enhanced HER2/HER2 homodimers and HER2/EGFR heterodimers internalization leading to potent antitumor activity in HER2-positive human gastric cancer
Efficacy and prognosis of HER2-Low and HER2-Zero in triple-negative breast cancer after neoadjuvant chemotherapy
HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry
Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level
Pathologic complete response and survival in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy
Comprehensive genomic characterization of HER2-low and HER2-0 breast cancer
Häufigkeit der EGFR- und HER2-Ausprägung sowie HER2-Genamplifikation beim Gallengangskarzinom
Single HER2-positive tumor cells are detected in initially HER2-negative breast carcinomas using the DEPArray™–HER2-FISH workflow
Differentiating HER2-low and HER2-zero tumors with 21-gene multigene assay in 2,295 HR + HER2- breast cancer: a retrospective analysis
Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
Survival outcomes in HER2-low versus HER2-zero breast cancer after neoadjuvant chemotherapy: a meta-analysis
HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates
Dual targeting non-overlapping epitopes in HER2 domain IV substantially enhanced HER2/HER2 homodimers and HER2/EGFR heterodimers internalization leading to potent antitumor activity in HER2-positive human gastric cancer
Efficacy and prognosis of HER2-Low and HER2-Zero in triple-negative breast cancer after neoadjuvant chemotherapy
HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry
Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level
Pathologic complete response and survival in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy
Comprehensive genomic characterization of HER2-low and HER2-0 breast cancer
Häufigkeit der EGFR- und HER2-Ausprägung sowie HER2-Genamplifikation beim Gallengangskarzinom
Single HER2-positive tumor cells are detected in initially HER2-negative breast carcinomas using the DEPArray™–HER2-FISH workflow
Differentiating HER2-low and HER2-zero tumors with 21-gene multigene assay in 2,295 HR + HER2- breast cancer: a retrospective analysis
Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
Survival outcomes in HER2-low versus HER2-zero breast cancer after neoadjuvant chemotherapy: a meta-analysis
HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates
Dual targeting non-overlapping epitopes in HER2 domain IV substantially enhanced HER2/HER2 homodimers and HER2/EGFR heterodimers internalization leading to potent antitumor activity in HER2-positive human gastric cancer
Efficacy and prognosis of HER2-Low and HER2-Zero in triple-negative breast cancer after neoadjuvant chemotherapy
HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry
Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level
Pathologic complete response and survival in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy
Comprehensive genomic characterization of HER2-low and HER2-0 breast cancer
Häufigkeit der EGFR- und HER2-Ausprägung sowie HER2-Genamplifikation beim Gallengangskarzinom